In the future, pharmacological manipulation of the diabetes/VEGF/aPKC pathway may provide a new strategy for preventing perturbations in retinovascular function from progressing to irreversible sight‐impairing diabetic retinopathy. Here, VEGFA is linked to diabetes mellitus.